Alife Health’s AI embryo selection tool gains CE mark
October 24, 2025
The tool integrates with the current laboratory infrastructure, captures images of embryos and creates an AI score.
The tool integrates with the current laboratory infrastructure, captures images of embryos and creates an AI score.
FRANKLIN LAKES, N.J., Oct. 22, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System.
ALLENDALE, N.J., Oct. 22, 2025 /PRNewswire/ — iNPLANT LLC, a leader in surgical innovation, today announced the release of the iNPLANT XL Funnel, a next-generation surgical device designed for the insertion of large breast implants (800cc–1500cc) using the “No-touch” surgical technique. The XL Funnel is the only device engineered specifically for this size range, addressing a critical unmet need in reconstructive and aesthetic breast surgery.
The initiative is set to continue until the end of 2025, with backing from Google.org.
Vara has announced that it has received a new CE certificate for its new breast-imaging AI.
Designed alongside HCA Healthcare, CareIntellect aims to simplify patient monitoring in perinatal care.
Researchers at McMaster University have developed a new menstrual health product designed to complement and enhance an existing menstrual cup that is safer, easier to use and more environmentally sustainable than current options.
The ticking of the biological clock is especially loud in the ovaries—the organs that store and release a woman’s eggs. From age 25 to 40, a woman’s chance of conceiving each month decreases drastically.
MedTech Innovator held its Grand Prize Finals at AdvaMed’s the MedTech Conference, with Armor Medical coming away the winner.
A new way of diagnosing heavy bleeding after birth (postpartum hemorrhage or PPH) is more effective at identifying women in need of treatment than the current diagnostic method, suggests a meta-analysis published in The Lancet.